
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp demonstrated a solid financial performance characterized by an increase in gross margin by 50 basis points year-over-year and an impressive rise in adjusted EBITDA margin by 280 basis points. The company's Trauma & Deformity sales grew by 17.3% to $44.1 million, outperforming estimates, and management highlighted a significant growth rate of over 20% in the OPSB category for the third quarter of 2025. Looking ahead, the company anticipates continued revenue growth of over 12% in the coming years, with expectations for improved margins driven by new product introductions and enhanced operating leverage.
Bears say
The analysis of OrthoPediatrics Corp reveals several fundamental concerns that contribute to a negative outlook on the stock. Key financial metrics indicate a slowdown in revenue growth, with the KIDS segment experiencing a decline from 15.7% in Q2 2025 to 12.2% in Q3 2025, raising fears of further stagnation amidst challenges related to sales rep attrition and new product launches. Additionally, declining productivity gains among distributors and a drop in deployed sets from $5.3 million in Q3 2024 to $4.1 million in Q3 2025 suggest potential weaknesses in revenue generation and margin improvement, prompting a downward revision of FY25 guidance to between $233.5 million and $234.5 million.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares